Stockreport

Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval [Seeking Alpha]

Outlook Therapeutics, Inc.  (OTLK) 
Last outlook therapeutics, inc. earnings: 2/14 08:00 am Check Earnings Report
PDF Phase 3 NORSE EIGHT study underway using ONS-5010 for the treatment of patients with Wet-AMD; Data expected to be released in Q4 of 2024. Pending the primary endpoint [Read more]